2016 Press Releases

Webcast ImageWebcast
Chromadex Corp at the 11th Annual LD Micro Main Event (Replay)
12/05/18 at 4:30 p.m. PT
Chromadex Corp at the 11th Annual LD Micro Main Event
Wednesday, December 5, 2018 4:30 p.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
12/01/16ChromaDex to Present at the 3rd Annual Bernstein Consumer Summit on December 8, 2016
IRVINE, Calif., Dec. 01, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that its Chief Executive Officer and Founder, Frank Jaksch, will present at the 3rd Annual Bernstein Consumer Summit. The investor summit will be held on Dec. 7-8, 2016 at the New York Hilt... 
Printer Friendly Version
11/11/16ChromaDex Announces the Results of Pre-IND meeting for Nicotinamide Riboside for Cockayne Syndrome
IRVINE, Calif., Nov. 11, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it has completed a pre-IND meeting with the U.S. Food and Drug Administration (FDA) on Nov. 1, 2016. During the meeting, ChromaDex and the FDA discussed the development plan for nicotina... 
Printer Friendly Version
11/10/16ChromaDex Reports Third Quarter 2016 Financial Results
-Company Reports Revenue of $21.2 million for first 9 months 2016 and is on track for another record revenue year -Company Reports Revenue of $5.0 million for Q3 2016 -Accelerating trend of peer-reviewed research validating NR continued during Q3 IRVINE, Calif., Nov. 10, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sp... 
Printer Friendly Version
11/08/16ChromaDex Establishes $5 Million Credit Facility with Bridge Bank
IRVINE, Calif., Nov. 08, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it has established a $5 million credit facility with Bridge Bank. The credit facility will provide ChromaDex non-dilutive working capital needed for future growth as the company contin... 
Printer Friendly Version
11/07/16ChromaDex Names Dr. Matthew Roberts as a New Scientific Advisory Board Member
Company’s Scientific Advisory Board Will Be Comprised of a Diverse Range of Experts with an Emphasis on Nicotinamide Riboside IRVINE, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today it has appointed Dr. Matthew Roberts, Ph.D. to the Company’s Sci... 
Printer Friendly Version
11/04/16ChromaDex to Attend the Torrey Hills Capital 2nd Annual Emerging Growth Conference on November 11, 2016
IRVINE, Calif., Nov. 04, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that its Chief Executive Officer and Founder, Frank Jaksch, will attend the Torrey Hills Capital 2nd Annual Emerging Growth Conference. The investor conference will be held on Nov. 10-12, 2... 
Printer Friendly Version
11/03/16ChromaDex to Report Third Quarter 2016 Financial Results on Thursday, November 10, 2016
Company Will Host Investor Conference Call on Thursday, November 10, 2016 IRVINE, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it plans on reporting its third quarter 2016 financial results on Thursday, Nov. 10, after the close of the f... 
Printer Friendly Version
10/27/16ChromaDex Appoints Kurt Gustafson to its Board of Directors
IRVINE, Calif., Oct. 27, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that Kurt Gustafson has joined the Company’s board of directors. Mr. Gustafson will also serve as chair of ChromaDex’s audit committee. Mr. Gustafson, age 48, has more than 25 years of dive... 
Printer Friendly Version
10/24/16Nicotinamide riboside (NR) plays a critical role in the most efficient path to cellular energy production
Researchers’ findings disprove the idea that there’s a shortcut to NAD production IRVINE, Calif., Oct. 24, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition and pharmaceutical products, announced today that an additional study recently published in the prestigious journal, Nature Communications, explains why ... 
Printer Friendly Version
10/10/16Published studies in humans and mice reveal how a superior vitamin B3 may play an important role in helping us enjoy longer, healthier lives
This vitamin, called NR, is exciting researchers as they discover more about its power to give us a more youthful metabolism IRVINE, Calif., Oct. 10, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that results from three studies, including its first human clini... 
Printer Friendly Version
10/03/16ChromaDex Adds New AnthOrigin™ to Its Proprietary Ingredient Portfolio
AnthOrigin™ naturally extracted anthocyanins are ideal for natural, clean label supplement innovation IRVINE, Calif., Oct. 03, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it has added its new AnthOrigin™ naturally extracted anthocyanins (≥15%) product to... 
Printer Friendly Version
09/22/16Leading Supplement Retailer Features NIAGEN® as Their Hot Ingredient for Fall, 2016
NR and NAD+ gaining more attention as consumers continue to look for ways to rejuvenate their energy IRVINE, Calif., Sept. 22, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced leading supplement retailer, Vitamin Shoppe, featured NIAGEN® nicotinamide riboside (NR) i... 
Printer Friendly Version
09/15/16Update: ChromaDex will demonstrate how it’s raising the bar on ingredient technology, applications innovation and raw materials testing at SupplySide West 2016
Booth to feature a new ingredient introduction, information on the latest published clinical trials, and a new time-saving solution to ensure your products deliver on their promise IRVINE, Calif., Sept. 15, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it... 
Printer Friendly Version
09/15/16ChromaDex will demonstrate how it’s raising the bar on ingredient technology, applications innovation and raw materials testing at SupplySide West 2016
Booth to feature, a new ingredient introduction, information on the latest published clinical trials, and a new time-saving solution to ensure your products deliver on their promise IRVINE, Calif., Sept. 15, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that i... 
Printer Friendly Version
08/30/16ChromaDex to Present at the Rodman & Renshaw 18th Annual Global Investment Conference on September 13, 2016
IRVINE, Calif., Aug. 30, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that its Chief Executive Officer and Founder, Frank Jaksch, will present at the Rodman & Renshaw 18th Annual Global Investment Conference. The investor conference will be held on Sept. ... 
Printer Friendly Version
08/15/16U.S. FDA issues GRAS No Objection Letter for NIAGEN®
NR, a vitamin B3, affords food and beverage manufacturers a new opportunity to innovate IRVINE, Calif., Aug. 15, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that the U.S. Food and Drug Administration (FDA) has issued a generally recognized as safe (GRAS) No O... 
Printer Friendly Version
08/11/16ChromaDex Reports Record Revenue as Ingredients Sales Climb 83% Compared to Previous Year Period
-Company Reports Record Revenue of $8.8 Million and Operating Income of $371,000- IRVINE, Calif., Aug. 11, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today record revenue for the second quarter ended July 2, 2016.  Results of operations for the three months e... 
Printer Friendly Version
08/10/16Scientists Find Important Clue to Restoring Muscle Function That’s Lost as We Age
Published study in mice points to the potential of a form of vitamin B3 referred to as NR to trigger this regenerative process  IRVINE, Calif., Aug. 10, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that University of Pennsylvania researchers have uncovered... 
Printer Friendly Version
08/02/16ChromaDex to Report Second Quarter 2016 Financial Results on Thursday, August 11, 2016
-Company Will Host Investor Conference Call on Thursday, August 11, 2016- IRVINE, Calif., Aug. 02, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it plans on reporting its second quarter 2016 financial results on Thursday, August 11, after the close of th... 
Printer Friendly Version
07/20/16ChromaDex Clinical Trial Studying NIAGEN® Well Underway, With Eight Additional Collaborative Human Studies Active
Study results will help to define the effective dose range of nicotinamide riboside (NR) in humans when taken daily, over eight weeks. IRVINE, Calif., July 20, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that the study of NIAGEN® - nicotinamide riboside is w... 
Printer Friendly Version
06/30/16ChromaDex Vindicated by Retraction and Apology from Author of Misleading and Factually Inaccurate Article
IRVINE, Calif., June 30, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), a leading provider of proprietary science-backed technologies and analytical services for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that an article by Bleecker Street Research published on Seeking Alpha on June 20, 2016 has been removed and replaced with an apology from the author. The following message has replaced the article: “This artic... 
Printer Friendly Version
06/28/16ChromaDex Added to the Russell 2000® Index
IRVINE, Calif., June 28, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), a leading provider of  proprietary science-backed technologies and analytical services for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today announced that the company has been added to the Russell 2000®, the Russell 3000®, the Russell Microcap® Index and the Russell Global Index at the conclusion of the Russell US Indexes annual reconstitution, effect... 
Printer Friendly Version
06/20/16ChromaDex Responds to Short Attack
IRVINE, Calif., June 20, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it plans to respond to a report published today by an anonymous party on a stock-discussions website. Frank L. Jaksch, Founder and CEO, ChromaDex, stated, "The report appears to be ... 
Printer Friendly Version
06/07/16ChromaDex Names Former Chairman & CEO of The Quaker Oats Company, William Smithburg, to its Board of Directors
IRVINE, Calif., June 07, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that William Smithburg has joined the Company's board of directors as an independent director.  Smithburg, age 77, joined The Quaker Oats Company in 1966 as a brand manager, becoming vic... 
Printer Friendly Version
06/06/16ChromaDex Announces $5.25 Million Registered Direct Offering
IRVINE, Calif., June 06, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it has entered into an agreement with one investor to purchase $5.25 million of the Company’s common stock in a registered direct offering. The fees associated with this transaction w... 
Printer Friendly Version
06/01/16University Researchers Show Vitamin Nicotinamide Riboside is an Effective Tool for Managing the Negative Effects of Obesity and Diabetes
New published study shows a unique form of vitamin B3, nicotinamide riboside, may help with weight gain and glycemic control as well as protect nerves from diabetic damage IRVINE, Calif., June 01, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that researcher... 
Printer Friendly Version
05/25/16ChromaDex to Present at the 2016 Marcum MicroCap Conference on June 1, 2016
IRVINE, Calif., May 25, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today its Chief Financial Officer, Tom Varvaro, will present at the 2016 Marcum MicroCap Conference. The investor conference will be held on June 1-2, 2016 at the Grand Hyatt New York in New York,... 
Printer Friendly Version
05/18/16ChromaDex to Present at the 17th Annual B. Riley & Co. Investor Conference on May 26, 2016
IRVINE, Calif., May 18, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today its Chief Executive Officer and Founder, Frank Jaksch, will present at the 17th Annual B. Riley & Co. Investor Conference. The investor conference will be held on May 25-26, 2016 at the ... 
Printer Friendly Version
05/16/16ChromaDex Names Will T. Black to its Executive Team as Vice President, Sales and Marketing
IRVINE, Calif., May 16, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that Will Black has joined the company as Vice President of Sales and Marketing. Black has held multiple leadership positions in the nutrition and health industry over the last 25 years. ... 
Printer Friendly Version
05/12/16ChromaDex Reports Record Revenue and Quarterly Net Income as Ingredients Sales Climb 72%
-Company Records Net Income of $256,000 as Company Reports Record Revenue of $7.3 Million- IRVINE, Calif., May 12, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today record revenue for the first quarter ended April 2, 2016.  Results of operations for the three m... 
Printer Friendly Version
05/10/16ChromaDex to Report First Quarter 2016 Financial Results on Thursday, May 12, 2016
Company Will Host Investor Conference Call on Monday, May 16, 2016 IRVINE, Calif., May 10, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it plans on reporting its first quarter 2016 financial results on Thursday, May 12, before the open of the financial ... 
Printer Friendly Version
04/28/16ChromaDex to Present at the Drexel Hamilton Micro Cap Investor Forum on May 12, 2016
IRVINE, Calif., April 28, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today its Chief Executive Officer and Founder, Frank Jaksch, will present at the Drexel Hamilton Micro Cap Investor Forum. The investor forum will be held on May 12, 2016 at the offices of Drex... 
Printer Friendly Version
04/25/16ChromaDex to Begin Trading on The NASDAQ Capital Market Today
IRVINE, Calif., April 25, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), formerly (OTCQX:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, today announced that the Company's common stock will be eligible to trade on The NASDAQ Capital Market under the symbol "CDXC" upon the open of the market today. The NASDAQ Stoc... 
Printer Friendly Version
04/21/16ChromaDex Approved for Listing on The NASDAQ Capital Market
-Company Will Begin Trading on NASDAQ on Monday, April 25, 2016- IRVINE, Calif., April 21, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (OTCQX:CDXCD) (OTCQX:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that The NASDAQ Stock Market LLC has approved the Company's application to list its common stock on The NASD... 
Printer Friendly Version
04/19/16NECTAR7 Launches NIAGEN® & Collagen Dietary Supplement
IRVINE, Calif., April 19, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (OTCQX:CDXCD) (OTCQX:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that NECTAR7 has released a new product, NIAGEN® & COLLAGEN featuring ChromaDex’s lead ingredient, NIAGEN®. Jeromy Stallings, President of NECTAR7 Media commented, “NEC... 
Printer Friendly Version
04/13/16Thorne Research Announces Clinical Study to Assess Nicotinamide Riboside on Brain NAD+ in College Football Players
- Mayo Clinic, University of Minnesota, and ChromaDex to Collaborate on Study - IRVINE, Calif., April 13, 2016 (GLOBE NEWSWIRE) -- Thorne Research and ChromaDex Corp. (OTCQX:CDXC) announced today a research endeavor with Mayo Clinic and the University of Minnesota Clinical and Translational Science Institute, regarding a planned clinical study to assess the effect of Nicotinamide Riboside (NR) on brain NAD+ in college football players.  The randomized, placebo controlled, double-blind study ... 
Printer Friendly Version
04/12/16ChromaDex Announces Reverse Stock Split as Company Seeks to List its Common Stock on The NASDAQ Capital Market
IRVINE, Calif., April 12, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (OTCQX:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today  a reverse stock split of its shares of common stock at a ratio of 1-for-3. At the market open on Wednesday, April 13, 2016, ChromaDex common stock will begin trading on a split-adjusted b... 
Printer Friendly Version
03/17/16ChromaDex Reports 2015 Record Revenue as Ingredient Sales Grew 83%
- Company Expects to Report Record Revenue for Q1 2016 - - Led by NIAGEN®, Company Expects Strong Revenue Growth in 2016 - IRVINE, Calif., March 17, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (OTCQX:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, reported today record net revenue of $22.0 million for the year ended January 2... 
Printer Friendly Version
03/10/16ChromaDex to Report Year End 2015 Financial Results on Thursday, March 17, 2016
Company Will Host Investor Conference Call on Monday, March 21, 2016 IRVINE, Calif., March 10, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (OTCQX:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it plans on reporting its year end 2015 financial results on Thursday, March 17, after the close of the financial ... 
Printer Friendly Version
03/10/16ChromaDex Initiates Second Human Clinical Study on NIAGEN® -The World’s First and Only Commercially Available Form of Nicotinamide Riboside (NR)
- Broader Study Will Build Upon the Successful Results of the First Trial Which Demonstrated NIAGEN® is a Safe, Effective NAD+ Precursor in Humans - IRVINE, Calif., March 10, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (OTCQX:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today the initiation of the second human clini... 
Printer Friendly Version
03/01/16ChromaDex to Present at the 28th Annual ROTH Conference on March 15, 2016
IRVINE, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (OTCQX:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today its Chief Executive Officer and Founder, Frank Jaksch will present at the 28th Annual ROTH Conference. The conference is being held on March 13-16, 2015 at The Ritz Carlton Hotel in Dana Po... 
Printer Friendly Version
02/22/16ChromaDex Announces Commencement of an Obesity-Related Clinical Study of NIAGEN® in Collaboration With the University of Copenhagen and Aarhus University
Dr. Jonas Treebak, a Researcher With The Novo Nordisk Foundation Center for Basic Metabolic Research (University of Copenhagen, Denmark) Will, in Collaboration With Researchers at Aarhus University, Investigate the Metabolic and Insulin Sensitizing Effects of NIAGEN® in Obese Healthy Adults Aged 40-70 Years IRVINE, Calif., Feb. 22, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (OTCQX:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solution... 
Printer Friendly Version
02/17/16ChromaDex Named to 2016 OTCQX Best 50
IRVINE, Calif., Feb. 17, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (OTCQX:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today it has been named to the 2016 OTCQX® Best 50, a ranking of top performing companies traded on the OTCQX Best Market last year.  The OTCQX Best 50 is an annual ranking of the top 50 U.S. an... 
Printer Friendly Version
01/27/16ChromaDex Announces Retail Commercialization Deal With BPI Sports
- Deal with BPI Sports to Result in the Launch of Several New Products Containing NIAGEN® at Thousands of Nationwide Retail Locations - IRVINE, Calif., Jan. 27, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (OTCQX:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today a retail commercialization deal with BPI Sports for i... 
Printer Friendly Version
01/21/16NIAGEN® Launches at GNC Stores Nationwide
LIGHTHOUSE POINT, Fla., Jan. 21, 2016 /PRNewswire/ -- Specialty Nutrition Group, Inc. has announced the release of NIAGEN® in GNC stores nationwide, as part of its innovation partnership with the world's largest retailer of nutrition products. NIAGEN® will be marketed under the F1RST® brand of patented and research-backed single-ingredient products in GNC stores. --> --> ChromaDex Corp. (OTCQX: CDXC), is the innovator of NIAGEN®, its patented and clinically studied form of nicotina... 
Printer Friendly Version
01/06/16A Letter From the ChromaDex Chief Executive Officer
IRVINE, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- The following is issued on behalf of ChromaDex: Dear Fellow Shareholders: Ten years ago, we had the foresight to identify nicotinamide riboside (NR), a form of Vitamin B3, as a potential blockbuster in the emerging category of NAD+ precursors. Importantly, we were able to acquire all of the significant IP surrounding NR and register the tradename NIAGEN®. We now find ChromaDex in the enviable position of gatekeeper to the entire NAD+ precurs... 
Printer Friendly Version
01/04/16ChromaDex Lead Ingredient NIAGEN® Nicotinamide Riboside Achieves GRAS Status
- NIAGEN® Also Recently Received New Dietary Ingredient (NDI) Status From the FDA - IRVINE, Calif., Jan. 04, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (OTCQX:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that an independent scientific panel of experts determined that NIAGEN®, ChromaDex’s patented and propriet... 
Printer Friendly Version